Is Tandem stock a buy?
Tandem Diabetes Care finds support from accumulated volume at $53.60 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Our recommended stop-loss: We hold a negative evaluation for this stock.
Is Tandem Diabetes a buy?
Tandem Diabetes Care, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of TNDM, demonstrate its potential to underperform the market. It currently has a Growth Score of B.
Will Tndm go up?
The 12 analysts offering 12-month price forecasts for Tandem Diabetes Care Inc have a median target of 127.50, with a high estimate of 200.00 and a low estimate of 90.00. The median estimate represents a +107.99% increase from the last price of 61.30.
Who manufactures tandem insulin pumps?
Tandem Diabetes Care is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy. Tandem Diabetes Care, Inc. U.S.
Does tandem own DexCom?
Under the terms of the Agreement, Tandem will pay DexCom a technology license fee of $3 million , reimburse DexCom's development, clinical and regulatory expenses, and upon commercialization of the combined system, Tandem will pay DexCom a royalty of $100 for each CGM-enabled insulin pump sold. About DexCom, Inc.
Does tandem work with DexCom?
Advanced Options. The t:slim X2 pump can be used as a stand‑alone insulin pump, or it can be integrated with Dexcom G6 CGM. Using CGM allows you to enable one of our two predictive technologies, which helps manage insulin delivery — all to more confidently live your life.
When is Tandem Diabetes Care's earnings date?
Tandem Diabetes Care has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 3rd, 2022...
How can I listen to Tandem Diabetes Care's earnings conference call?
The conference call for Tandem Diabetes Care's latest earnings report can be listened to online. Listen to Conference Call
How can I read Tandem Diabetes Care's conference call transcript?
The conference call transcript for Tandem Diabetes Care's latest earnings report can be read online. Read Transcript
How can I view Tandem Diabetes Care's earnings report?
Tandem Diabetes Care's earnings report can be found in their filing with the SEC. View SEC filing
How much revenue does Tandem Diabetes Care generate each year?
Tandem Diabetes Care (NASDAQ:TNDM) has a recorded annual revenue of $702.80 million.
How much profit does Tandem Diabetes Care generate each year?
Tandem Diabetes Care (NASDAQ:TNDM) has a recorded net income of $15.57 million. TNDM has generated $0.08 earnings per share over the last four quar...
What is Tandem Diabetes Care's price-to-earnings ratio?
Tandem Diabetes Care (NASDAQ:TNDM) has a trailing price-to-earnings ratio of 825.35 and a forward price-to-earnings ratio of 183.39.
What is Tandem Diabetes Care's EPS forecast for next year?
Tandem Diabetes Care's earnings are expected to grow from $0.36 per share to $1.10 per share in the next year, which is a 205.56% increase.
Tandem Diabetes Care (NASDAQ:TNDM) Earnings Estimates
Enter your email address below to receive the latest news and earnings results for TNDM and its competitors with MarketBeat's FREE daily newsletter.
Tandem Diabetes Care (NASDAQ:TNDM) Earnings Frequently Asked Questions
Tandem Diabetes Care has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 3rd, 2022 based off last year's report dates. Learn more on TNDM's earnings history
Prepared Remarks
Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care Second Quarter 2021 Earnings Conference Call. [Operator Instructions]
Questions and Answers
Thank you. [Operator Instructions] Our first question comes from Steven Lichtman with Oppenheimer and Company. Your line is open.
Call participants
Susan Morrison -- Executive Vice President And Chief Administrative Officer
How much did Tandem Diabetes invest in 2020?
Tandem Diabetes exited the second quarter with cash and cash equivalents, and short-term investments of $426.3 million compared with $160.2 million recorded at the end of the first quarter of 2020.
How much is Zacks's 2020 revenue?
This represents annual sales growth of 24-28% compared to 2019. The Zacks Consensus Estimate for 2020 revenues is pegged at $416.1 million.
Q2 in Detail
Tandem Diabetes registered international sales of $20 million in the quarter under review, recording a 13% plunge from second-quarter 2019. Domestic sales came in at $89.3 million, up 27% year on year.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
The company believes that the surge in domestic pump shipments resulted from the appeal of the easy-to-use pump with the ability to offer remote software updates and rising customer awareness of its Control-IQ technology.
Margins
Gross profit in the June-end quarter was $54.4 million, marking an 8.9% year-over-year growth. Gross margin was, however, 49.8%, down 372 basis points (bps).
Financial Position
Tandem Diabetes exited the second quarter with cash and cash equivalents, and short-term investments of $426.3 million compared with $160.2 million recorded at the end of the first quarter of 2020.
2020 Guidance
Based on the strength in demand for t:slim X2 insulin pump across the globe, Tandem Diabetes has reinstated the sales guidance set at the beginning of 2020.
Our Take
Tandem Diabetes delivered better-than-expected results in the second quarter. A robust top line despite the pandemic-led business disruptions is impressive. Strong domestic pump sales and pump shipments buoy optimism.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Revenues
Revenues in the quarter came in at $172.1 million, up 57.6% year over year and beating the Zacks Consensus Estimate by 19%. The strength in the top line was driven by new customer demand and increasing renewal purchases from the company’s installed base.
Quarter in Detail
Tandem Diabetes registered international sales of $44.6 million in the quarter under review, recording a 123% rise from second-quarter 2020. Domestic sales totaled $127.6 million, up 43% year over year.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
The company believes that surge in pump shipments resulted from continued adoption of t:slim X2 technology by both new and existing customers and more healthcare providers prescribing the t:slim X2 than ever before.
Margins
Gross profit in the second quarter was $92.5 million, marking 69.9% year-over-year growth. Gross margin was 53.7%, indicating an expansion of 392 basis points (bps).
Financial Position
Tandem Diabetes exited second-quarter 2021 with cash and cash equivalents, and short-term investments of $545.3 million compared with $513.4 million at the end of first-quarter 2021.
2021 Sales Guidance Raised
For 2021, the sales projection has been raised to $670-$685 million, indicating annual sales growth of 34% to 37% (earlier projection for 2021 was in the range of $625-$640 million). The Zacks Consensus Estimate for 2021 revenues is pegged at $634.71 million.
Our Take
Tandem Diabetes delivered better-than-expected revenues for the second quarter of 2021. The topline registered year-over-year growth despite pandemic-led business disruptions. Solid performance in the quarter was driven by both new customer demand and increasing renewal purchases from the company’s installed base.